Morgan Stanley raised the firm’s price target on Exelixis (EXEL) to $50 from $49 and keeps an Equal Weight rating on the shares after the company shared updates across its zanza pipeline, highlighting the planned expansion into additional indications and key catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Kept at Hold as Cabo Momentum Offsets Pipeline Uncertainty; Price Target Raised from $49 to $50
- Exelixis Price Target Raised to $55 on Cabo Strength, Buyback-Driven EPS Growth, and Zanzalintinib Upside Optionality
- Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases
- Exelixis Posts Strong Q1 Results, Expands Share Buybacks
- EXEL Earnings this Week: How Will it Perform?